PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
CNNMoney The Company has also granted the underwriters a 45-day option to purchase up to an additional 525,000 shares of common stock and/or 525,000 warrants to cover over-allotments, if any. H.C. Wainwright & Co. and Aegis Capital Corp. are acting as joint … |